Teva expands portfolio with new injectable products

JERUSALEM — Teva Pharmaceuticals on Tuesday announced the launch of generic versions of Lovenox (enoxaparin sodium injection) as well as generic Zyvox (linezolid) injection. 

 

The company's generic Lovenox, available in seven dosage strengths, is used to treat deep vein thrombosis. The drug had sales in the United States of $1.8 billion as of November 2014, according to IMS data. Linezolid injection is indicated to treat infections brought on by Gram-positive bacteria, the company stated. The drug had annual sales of $464 million as of October 2014, according to IMS data. 

 

“With the launch of enoxaparin sodium injection, USP and linezolid injection, accompanied by the reintroduction of three generic injectable products, we are leveraging the strength of our internal and external resources to deliver the right portfolio as part of our growth strategy," said Siggi Olafsson, president and CEO of Teva Global Generic Medicines.